CHI3L1

Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics

Retrieved on: 
Tuesday, November 14, 2023
Yale University, Lung, Canadian Tire money, Brain, Research, AstraZeneca, Therapy, Joint venture, IND, Non-small-cell lung cancer, Disease, Clinical trial, Osimertinib, Patient, HBV, International joint venture, Immunotherapy, Animal, Neoplasm, TKI, Lung cancer, MD, Person, Infection, NSCLC, Human, SITC, BioRxiv, Malaria, Society, EGFR, Brown University Graduate School, Fibrosis, Pharmaceutical industry, Vaccine, CHI3L1, Cancer, Ocean, Virus

These new data demonstrate complete and highly reproducible tumor clearance, and protection upon tumor rechallenge, months after animals cleared their initial tumors.

Key Points: 
  • These new data demonstrate complete and highly reproducible tumor clearance, and protection upon tumor rechallenge, months after animals cleared their initial tumors.
  • VRON-0300 IND-enabling activities are underway, with the goal of filing its first IND within the next 9 months.
  • Virion Therapeutics is developing novel immunotherapies that utilize proprietary genetically encoded checkpoint modifiers (CPMs) to enhance and broaden CD8+ T cells responses.
  • Preclinical studies using CPMs have shown consistent and extraordinary immune responses and clinical activity in different diseases.

Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a Disease Affecting 300+ Million Patients Worldwide

Retrieved on: 
Thursday, October 12, 2023
Cancer, Research, CHI3L1, Brain, Therapy, IND, Disease, Person, Malaria, HBV, Canadian Tire money, Lung, Luber, Fibrosis, Patient, Pharmaceutical industry, Vaccine, Virus

Virion has begun enrolling a multi-national, first-in-humans study, “VRON-0200,” for the treatment of persons with chronic hepatitis B virus (HBV) infection, with the goal of providing a functional cure for a disease that affects over 300 million patients worldwide.

Key Points: 
  • Virion has begun enrolling a multi-national, first-in-humans study, “VRON-0200,” for the treatment of persons with chronic hepatitis B virus (HBV) infection, with the goal of providing a functional cure for a disease that affects over 300 million patients worldwide.
  • “We are pleased to be entering into this joint venture with Virion.
  • We are also excited to help support their oncology program, which is targeted for IND submission in the next 9 months.
  • We look forward to rolling up our sleeves together and bringing our novel therapeutics to patients worldwide!”

American Lung Association Funds $13.6 Million in Research for a Future Free of Lung Disease

Retrieved on: 
Thursday, October 12, 2023
Havasupai Tribe v. the Arizona Board of Regents, Manning Innovation Awards, T helper cell, Immunotherapy, COVID-19, Omicron, Lung cancer, Tropism, Icahn School of Medicine at Mount Sinai, Asthma, University of Arizona, Natural killer T cell, Research, COPD, Boston University, Immunoglobulin E, University, Disease, Lung, Patient, Award, American Lung Association, CHI3L1, Canadian Lung Association, Immunology, Helminthiasis, Trustee, Research institute, Infection, SARS-CoV-2, RSV, TFH, Blood, Mount Sinai, Pharmaceutical industry, Vaccine, School

CHICAGO, Oct. 12, 2023 /PRNewswire/ -- Today, the American Lung Association Research Institute announced it awarded $13.6 million in research grants to fund 129 innovative projects to advance today's science to end the burden of lung disease tomorrow. Lung research is critical because one in 10 people in the U.S. are living with a lung disease and each year, millions of people are impacted by respiratory viruses like COVID-19 and influenza.

Key Points: 
  • Organization funds 129 promising research grants on lung cancer, asthma, COVID-19 and more
    CHICAGO, Oct. 12, 2023 /PRNewswire/ -- Today, the American Lung Association Research Institute announced it awarded $13.6 million in research grants to fund 129 innovative projects to advance today's science to end the burden of lung disease tomorrow.
  • Through the Awards and Grants Program, the Lung Association supports trailblazing research, novel ideas and innovative approaches.
  • The Lung Association's Awards and Grants Program promotes innovative research, collaboration, translation of discoveries and scientific exchange to transform today's science into tomorrow's solutions," said Harold Wimmer, President and CEO of the American Lung Association.
  • For more information about the new grant awardees and the entire American Lung Association research team, visit Lung.org/research-team .

Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers

Retrieved on: 
Tuesday, October 3, 2023
Yale University, BioRxiv, RI, FRG, Osimertinib, Lung cancer, TUNEL, TKI, Research, Targeted therapy of lung cancer, Cell, Immunotherapy, AstraZeneca, Glioblastoma, Preprint, Gefitinib, Patient, EGFR, Growth, Neoplasm, Salvage therapy, Pharmaceutical industry, Vaccine, Dietary supplement, Medical imaging, Ocean Biomedical, CHI3L1, NSCLC, Cancer

Providence, RI, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announced today that its cancer-targeting immunotherapy antibody candidate has demonstrated effective tumor reduction against an aggressive subset of Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations. These research findings, which may be the most important Ocean Biomedical has announced to date, generated by Ocean’s Scientific Co-founder Dr. Jack A. Elias and colleagues from Yale University and Brown University, and first published as a preprint last week in bioRxiv, are the first to uncover the role of Chitinase 3-like-1 (CHI3L1) in the pathogenesis of EGFR-mutant cancers, with potential applications not just in NSCLC, but in all EGFR-mutant cancers, including glioblastoma and colon cancer.

Key Points: 
  • Additionally, the findings demonstrate a stunning ability to restore therapeutic sensitivity to current tyrosine kinase inhibitor (TKI) therapies after resistance sets in, including the third-generation TKI, Osimertinib (marketed as Tagrisso by AstraZeneca).
  • In 2022, AstraZeneca’s top pharmaceutical product by revenue was Tagrisso, a medication used in the treatment of non-small-cell lung carcinomas.
  • Non-Small Cell Lung Cancer (NSCLC) is a leading cause of cancer deaths globally, accounting for 85% of all lung cancers.
  • The EGFR-mutant lung cancer is found in 30%-50% of NSCLC patients with Asian heritage and 10%-20% of patients with Caucasian backgrounds.

Ocean Biomedical (NASDAQ: OCEA) Provides Latest Updates on its Broad Programs in Malaria, Fibrosis, and Multiple Cancers

Retrieved on: 
Thursday, August 10, 2023
Idiopathic disease, Melanoma, Idiopathic pulmonary fibrosis, Experiment, Doctor of Philosophy, Development, Patent, MD, Patient, Hermansky–Pudlak syndrome, Breast cancer, Brain, Prostate cancer, Malaria, Therapy, Climate, NASH, RI, Skin cancer, Research, Glioblastoma, Pulmonary fibrosis, Fatty liver disease, Response evaluation criteria in solid tumors, IPF, Death, Alcoholic liver disease, Monoclonal antibody, Kidney cancer, Lung cancer, Extension, Treatment of lung cancer, Messenger, Fibrosis, Science, Biomedicine, Cancer, Parasitism, Ovarian cancer, CHI3L1, Q&A, Lung, HPS, World Health Organization, Scleroderma, Medical device, Pharmaceutical industry, Vaccine, Medical imaging, Ocean Biomedical

Providence, RI, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, shared today an update on its broad range of promising programs in malaria, fibrosis, and multiple cancers.

Key Points: 
  • In addition to the multi-pronged cancer program, the Company is advancing a novel malaria vaccine candidate and a companion malaria drug program.
  • The Company is also working to advance a much-needed pulmonary fibrosis treatment candidate to raise the standard of care available to patients with pulmonary fibrosis.
  • “Our team is simultaneously targeting several major cancer pathways,” said Dr. Jack A. Elias, a Scientific Co-founder of Ocean Biomedical.
  • Similarly, malaria and the cancers we are targeting are not adequately addressed by the current therapeutics because of efficacy or side effect shortcomings.

Ocean Biomedical, Inc. (NASDAQ: OCEA) Celebrates 95% Lung Cancer Tumor Reduction Results on World Lung Cancer Day

Retrieved on: 
Tuesday, August 1, 2023
Non-small-cell lung cancer, Monoclonal antibody, CHI3L1, Executive, Therapy, Ocean Biomedical, RI, Kidney cancer, Cancer, Lung cancer, Breast, NSCLC, Cell, Prostate, Immunotherapy, Antibody, Glioblastoma, Lung, CTLA4, Patent, Patient, Melanoma, Immune system, Ovarian cancer, Metastasis, Breast cancer, Prostate cancer, Vaccine, Medical imaging, Pharmaceutical industry

Providence, RI, Aug. 01, 2023 (GLOBE NEWSWIRE) -- On World Lung Cancer Day, Ocean Biomedical, Inc. (NASDAQ: OCEA) is sharing details of its multi-pronged Lung Cancer Program built on novel immunotherapy discoveries by Scientific Co-founder Dr. Jack A. Elias. He and his team have revealed that Chitinase 3-like-1 (CHi3L1) is a master regulator that inhibits antitumor immune responses. Ocean Biomedical’s lung cancer program is advancing several approaches to reversing immune system suppression caused by CHi3L1 alone and in combination with other immunotherapy pathways. These programs suppress primary and metastatic tumor growth in multiple animal models and have potential use in multiple forms of visceral cancers. In recent studies, Ocean Biomedical’s programs have demonstrated up to 95% reduction in primary and metastatic tumor burden in mouse models of lung cancer.

Key Points: 
  • Ocean Biomedical’s first-in-class anti-CHi3L1 therapeutic immunotherapy program has shown compounding efficacy in multiple lung cancer models while simultaneously inhibiting multiple oncogenic pathways, including hard-to-treat Non-Small Cell Lung Cancer (NSCLC).
  • Providence, RI, Aug. 01, 2023 (GLOBE NEWSWIRE) -- On World Lung Cancer Day, Ocean Biomedical, Inc .
  • In recent studies, Ocean Biomedical’s programs have demonstrated up to 95% reduction in primary and metastatic tumor burden in mouse models of lung cancer.
  • In total, Ocean Biomedical’s oncology platform has garnered 27 issued or pending patents, already covering ‘method of use’ in nine unique cancers, including prostate cancer, colon cancer, rectal cancer, ovarian cancer, kidney cancer, breast cancer, glioblastoma, melanoma, and lung cancer.

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces U.S. Patent Issued for Bispecific Cancer Immunotherapy Treatment With Demonstrated Killing of Tumor Cells in Lung Cancer, Brain Cancer (Glioblastoma), and Metastatic Melanoma.

Retrieved on: 
Monday, June 26, 2023
Monoclonal antibody, CHI3L1, Executive, Therapy, RI, Kidney cancer, Research fellow, Cancer, Lung cancer, Research, Biology, Glioblastoma, Science, Patent, Patient, Melanoma, Brown University, Internal medicine, Alpert Medical School, Immunology, PD-1, Ovarian cancer, Breast cancer, Prostate cancer, Vaccine, Pharmaceutical industry, Medicine, Ocean Biomedical, MD

Providence, RI, June 26, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announced today that a new, broad U.S. patent for bispecific antibodies targeting chitinase 3-like-1 (CHi3L1) and programmed cell death protein 1 (PD-1), a promising new approach that has emerged from prior breakthrough discoveries that CHi3L1 is a “master regulator” of tumor growth in multiple visceral cancers, has been issued to one of its Scientific Co-founders, Dr. Jack A. Elias, MD.

Key Points: 
  • Ocean Biomedical’s bispecific antibody is a cutting-edge immunotherapy approach that demonstrates promising synergy by combining Ocean’s proprietary anti-CHi3L1 antibody with existing immune checkpoint inhibitors that target PD-1 in a bispecific-antibody format.
  • Ocean Biomedical’s breakthrough comes at a critical time for the evolving immuno-oncology sector, which is working to realize the promise of immune checkpoint inhibition.
  • Current challenges include the limited number of cancer patients demonstrating initial responses and the significant number of responders relapsing following classic immune checkpoint blockade.
  • The new bispecific patent has been granted for prostate cancer, colon cancer, rectal cancer, ovarian cancer, kidney cancer, breast cancer, glioblastoma, melanoma, and lung cancer.

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Award for Novel Cancer Immunotherapy Treatment, Granted for Prostate Cancer, Colon Cancer, Ovarian Cancer, Kidney Cancer, Breast Cancer, Glioblastoma, Melanoma, and Lung Cancer.

Retrieved on: 
Tuesday, May 23, 2023
CHI3L1, Executive, Therapy, RI, Kidney cancer, Research fellow, Cancer, Lung cancer, Biology, Glioblastoma, Science, Patent, Melanoma, Brown University, Immune system, Internal medicine, Alpert Medical School, Immunology, Ovarian cancer, Breast cancer, Prostate cancer, Pharmaceutical industry, Vaccine, Medicine, Ocean Biomedical, MD

Providence, RI, May 23, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) announced today that its Scientific Co-founder, Dr. Jack A. Elias, MD, has been issued a broad patent for his cancer immunotherapy discovery related to reversing immune system suppression by binding chitinase 3-like-1 (CHi3L1) polypeptides with Ocean Biomedical’s proprietary immunoglobulin antibody. This process has been shown to suppress primary and metastatic tumor growth in multiple animal models and has potential use in multiple forms of visceral cancers.

Key Points: 
  • This process has been shown to suppress primary and metastatic tumor growth in multiple animal models and has potential use in multiple forms of visceral cancers.
  • Ocean Biomedical’s monoclonal antibody is one component of a unique oncology platform that is building multiple approaches to activating natural anticancer immune responses by suppressing CHi3L1, with potential for broad application.
  • The patent has been granted for prostate cancer, colon cancer, rectal cancer, ovarian cancer, kidney cancer, breast cancer, glioblastoma, melanoma, and lung cancer.
  • The newest claims dovetail issued patents with claims coverage focused on composition of matter of monoclonal antibodies targeting and inhibiting CHi3L1.

Ocean Biomedical (NASDAQ: OCEA) Announces New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody

Retrieved on: 
Thursday, April 27, 2023
Yale University, Health Affairs, Therapy, Senior, GBM, Journal, Critical Care Medicine (journal), Prior, Cancer research, RI, Neoplasm, Ligand, University, Dean, Yale New Haven Hospital, Research, Cell, Lung cancer, Antibody, Doctor of Philosophy, Thought, Plasticity, MRI, CTLA4, Biology, Protein, Science, MD, Chandos Chair of Medicine and Anatomy, PTEN, Patient, Melanoma, Brown University, Apoptosis, Cancer, Mouse, Growth, PD-1, IND, PD-L1, Environment, Phenotype, Laboratory, Metastasis, Disease, Pharmaceutical industry, Medical imaging, Medical device, Vaccine, Glioblastoma, Frontiers, Ocean Biomedical, CHI3L1, Immunology, Medicine

Providence, RI, April 27, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling assets from research universities and medical centers, announced today that its Scientific Co-founder, Jack A. Elias, MD, published new findings in the peer-reviewed journal Cancer Research that detail the mechanisms behind the role of chitinase 3-like-1 (Chi3L1) in the growth of glioblastoma tumors, providing further evidence of the potential impact of Ocean’s anti-Chi3L1 antibody in suppressing severe glioblastoma tumor growth.

Key Points: 
  • In two different study approaches, treatment with anti-Chi3L1 antibody in vivo resulted in over 60% reduction of human glioblastoma growth, and significant survival benefit.
  • This represents a medical breakthrough in understanding how the most aggressive glioblastoma tumors are formed, and how patients diagnosed with this challenging disease might possibly be treated.
  • “This is a completely new way of thinking about how to treat this tumor.
  • Knowing the drivers for this heterogeneity, this is the holy grail for glioblastoma.”

$134 Million in Financial Backing for Innovative Research and IND Fillings Announced by Ocean Biomedical (NASDAQ: OCEA); Provides Latest Updates on Advancement of Platform, Novel Discoveries in Malaria, Pulmonary Fibrosis and Oncology

Retrieved on: 
Monday, April 17, 2023
Prevalence, CHI3L1, Ng, Doctor of Philosophy, Patent, Risk, Hermansky–Pudlak syndrome, Disease, Glioblastoma, Laboratory, DSM-IV codes, GBM, NASH, RI, Research, Infection, Brain, Pulmonary fibrosis, Growth, Alcoholic liver disease, IND, NIH, Metastasis, Idiopathic pulmonary fibrosis, Common stock, Parasitism, Ocean Biomedical, United States Patent and Trademark Office, Cancer, Lung cancer, NSCLC, Vaccine, Fibrosis, Science, Tuberculosis, Times Square, Non-small-cell lung cancer, Stanford University School of Medicine, University, Lung, HPS, Health, Scleroderma, Renewable energy, Pharmaceutical industry, Dietary supplement, MD, Malaria

Ocean visited the Nasdaq MarketSite in Times Square to ring the Opening Bell in its debut as a public company.

Key Points: 
  • Ocean visited the Nasdaq MarketSite in Times Square to ring the Opening Bell in its debut as a public company.
  • “We’re immensely pleased with the progress we’re making as a Company,” said Elizabeth Ng, Ocean’s CEO.
  • With the support of Ocean, these innovations can be more quickly delivered to those that desperately need them.
  • Moreover, the company’s drug target discovery platform can potentially discover targets against other infectious diseases, like tuberculosis or another pandemic-type virus.